Effect of Introduction of Authorized Generic Product of Rosuvastatin on the Switch from the Branded Product to Generic Drugs in a Community Pharmacy

DOI

この論文をさがす

抄録

The medical costs in Japan are rising owing to an increasing number of aged population and advances in medical technologies. Thus, there is an urgent need to reduce the ever- increasing medical costs while ensuring a high quality of medical care. Many countries adopt a policy for suppressing medical costs by promoting the usage of generic drugs that are less expensive than branded drugs. The present study investigated the effect of the recently introduced authorized generic (AG) system in Japan on the patients’ preference in switching the branded product of rosuvastatin, one of the first-line treatment for dyslipidemia drugs, either to the AG or non-AG products in a community pharmacy, Funabashi, Chiba. The results showed that 64.3% of the respondents preferred to use generic drugs, and those who preferred to use branded drugs were significantly older than those who preferred to use generic drugs (p=0.004). After the pharmacists’ counselling patients about AG and non-AG (standard) generic drug, 60% of patients who initially chose the branded product switched to AG drug. In conclusion, pharmacists’ adequate guidance and awareness to patients about AGs and non-AG (standard) generic drug may promote the use of generic drugs.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ